BELLUS Health Inc. (BLU): Price and Financial Metrics
GET POWR RATINGS... FREE!
BLU POWR Grades
- Stability is the dimension where BLU ranks best; there it ranks ahead of 51.37% of US stocks.
- The strongest trend for BLU is in Growth, which has been heading down over the past 179 days.
- BLU's current lowest rank is in the Quality metric (where it is better than 14.71% of US stocks).
BLU Stock Summary
- BLU's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 404.87 -- higher than 93.75% of US-listed equities with positive expected earnings growth.
- For BLU, its debt to operating expenses ratio is greater than that reported by just 5.11% of US equities we're observing.
- BLU's price/sales ratio is 112,881.9; that's higher than the P/S ratio of 99.98% of US stocks.
- Stocks that are quantitatively similar to BLU, based on their financial statements, market capitalization, and price volatility, are MRUS, RAPT, TSVT, XENE, and AGIO.
- Visit BLU's SEC page to see the company's official filings. To visit the company's web site, go to www.bellushealth.com.
BLU Price Target
For more insight on analysts targets of BLU, see our BLU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $7.20 | Average Broker Recommendation | 1.43 (Moderate Buy) |
BLU Stock Price Chart Interactive Chart >
BLU Price/Volume Stats
| Current price | $7.86 | 52-week high | $12.69 |
| Prev. close | $7.96 | 52-week low | $5.45 |
| Day low | $7.82 | Volume | 579,100 |
| Day high | $8.07 | Avg. volume | 630,220 |
| 50-day MA | $8.74 | Dividend yield | N/A |
| 200-day MA | $9.31 | Market Cap | 994.82M |
BELLUS Health Inc. (BLU) Company Bio
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Latest BLU News From Around the Web
Below are the latest news stories about BELLUS HEALTH INC that investors may wish to consider to help them evaluate BLU as an investment opportunity.
Is the BELLUS Health Inc. (NASDAQ:BLU) stock an investment opportunity?In the current trading session, BELLUS Health Inc.’s (BLU) stock is trading at the price of $8.39, a gain of 0.42% over last night’s close. So, the stock is trading at a price that is -33.92% less than its 52-week high of $12.69 and 68.37% better than its 52-week low of $4.98. Based on the […] |
Bellus Health: Building Momentum Around CALM, SOOTHE StudiesBELLUS Health Inc. is pushing ahead on this front, with recent support from evidence in its recent clinical trials. Click here to read why we rate BLU stock a hold. |
BELLUS Health Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsBELLUS Health ( TSE:BLU ) Third Quarter 2022 Results Key Financial Results Net loss: US$24.7m (loss widened by 8.0... |
BELLUS Health Reports Third Quarter 2022 Financial Results and Business HighlightsBELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics |
BELLUS Health to Participate in Two Upcoming Healthcare Investor ConferencesBELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics |
BLU Price Returns
| 1-mo | N/A |
| 3-mo | -12.18% |
| 6-mo | -32.42% |
| 1-year | 22.81% |
| 3-year | -3.68% |
| 5-year | 643.90% |
| YTD | -4.38% |
| 2022 | 2.11% |
| 2021 | 163.07% |
| 2020 | -59.74% |
| 2019 | 175.96% |
| 2018 | 155.26% |
Loading social stream, please wait...